ABBOTT LABORATORIES 8-K

What Happened
Abbott Laboratories (ABT) filed a Form 8‑K on April 16, 2026 to furnish a press release (Exhibit 99.1) announcing its results of operations and financial condition. In that release, Abbott reported its earnings information and highlighted various non‑GAAP financial measures, including "net earnings excluding specified items," which it uses to present operating performance excluding certain charges and tax items.

Key Details

• Filing date: April 16, 2026; press release furnished as Exhibit 99.1 (Item 2.02 and Item 9.01 referenced).
• Non‑GAAP measures cited include "net earnings excluding specified items" and results that exclude intangible amortization expense.
• Adjustments exclude items such as acquisition‑related expenses, stock‑based compensation accelerated for an acquisition, restructuring actions, certain regulatory costs, prior non‑cash deferred tax benefit adjustments, tax benefits tied to specified items, resolution of prior‑year tax positions, and excess tax benefits from share‑based compensation.
• Abbott’s management says it uses these non‑GAAP measures internally to monitor business performance but cautions investors to consider them alongside GAAP measures.

Why It Matters
The filing signals Abbott’s reported earnings and management’s emphasis on adjusted (non‑GAAP) results to show underlying operating performance. For investors, that means headline non‑GAAP figures may exclude items (acquisition costs, tax adjustments, amortization) that materially affect comparability with GAAP results and with peers. Review both the GAAP numbers and the specific adjustments disclosed in the press release to fully assess Abbott’s quarterly performance.